01

All exacerbations in patients receiving FASENRA Q8W in SIROCCO/CALIMA were treated with steroids.1

Protection from exacerbations requiring steroids1,2

FOOTNOTES

*Post-hoc, pooled analysis of SIROCCO (48 weeks) and CALIMA (56 weeks) patients on FASENRA every 8 weeks (n=506) or placebo (n=515) plus standard of care (SOC), which is defined as high-dose ICS/LABA (inhaled corticosteroids/long-acting β2-agonist) with or without other controllers, including systemic steroids.1

In BORA, patients from SIROCCO and CALIMA were to be maintained on their same dose of ICS/LABA (inhaled corticosteroids/long-acting β2-agonist).2

In patients with baseline blood eosinophil count ≥300 cells/µL and 2 or more exacerbations in the past year.5

Exacerbations Rate in Year 1
Exacerbations Rate in Year 1

Patients on Q8W dosing during SIROCCO/CALIMA (48 weeks/56 weeks)*1
50% of patients on placebo during SIROCCO/CALIMA (48 weeks/56 weeks) had 0 exacerbations.*1

Exacerbations Rate in Year 2
Exacerbations Rate in Year 2

Patients who continued on Q8W dosing from SIROCCO or CALIMA into BORA
(n=339, 56 weeks).†2

The analyses of these endpoints were not multiplicity protected. Results are descriptive only.

02

Protection from dependence on OCS3,4

In ZONDA (28 weeks), the primary endpoint was median percent reduction from baseline in final OCS dose while maintaining asthma control. OCS-dependent patients were defined as those requiring daily OCS.5

In patients taking daily oral corticosteroids.3-5

Median OCS Dose Percent from Baseline
Median OCS Dose Percent from Baseline

compared to 25% reduction with placebo + SOC in ZONDA (28 weeks)3

FASENRA (n=73); Placebo (n=75) (P<0.001)3,5

Annual Exacerbation Rate in ZONDA
Annual Exacerbation Rate in ZONDA

(0.02) compared to placebo + SOC (0.32) in ZONDA (28 weeks)*4,5

FASENRA (n=73); Placebo (n=75)

*The analysis of this endpoint was not multiplicity protected. Results are descriptive only.

In ZONDA, FASENRA and placebo were administered in addition to daily OCS (7.5 to 40 mg) plus SOC, which is defined as high-dose ICS/LABA with or without other controllers.5

Power to Prevent Exacerbations

Learn more about the efficacy of FASENRA in relation to exacerbation rate reduction and lung function data.

Dosing                    


Learn about convenient dosing and administration options.



Study
Designs

See full study descriptions for SIROCCO, CALIMA, BORA, ANDHI, and more.




IMPORTANT SAFETY INFORMATION